

Kastle Therapeutics Leadership Bios

Alan D. MacKenzie *Executive Chairman*

Alan retired from Takeda in 2011 after 26 years of service where he held numerous senior-level leadership positions. Alan was most recently a Member of the Board and the Executive Vice President of Takeda's International Operations where he oversaw all of Takeda's businesses outside Japan. Prior, Alan was President and CEO of Takeda Pharmaceuticals North America and was Takeda's founding non-Japanese executive for its U.S. operations in 1998. He began his pharmaceutical career at Takeda's joint venture with Abbott, TAP Pharmaceuticals, and returned to serve as its President and CEO in 2004 until the dissolution of TAP back to its parent companies in 2008.

Alan currently serves as a Senior Advisor to Flexpoint Ford, a leading private equity firm, on matters of investment in the pharmaceutical industry and other related life sciences companies.

Alan has previously served on the boards of Actient Pharmaceuticals LLC, Takeda Pharmaceutical Corporation Ltd, TAP Pharmaceutical Products Inc., and was a Director of the Pharmaceutical Research and Manufacturers of America (PhRMA). Alan holds a Bachelor of Science in Nursing from Wagner College and earned his Master of Business Administration from the Graduate School of Business, The University of Chicago.

Bryan E. Stuart *President*

Bryan has over 15 years of experience building life sciences companies. He was most recently the Chief Business Officer of Civitas Therapeutics. At Civitas, Bryan was responsible for raising capital, business development, commercial and strategy functions, including the IPO and company sale of Civitas to Acorda Therapeutics (NASDAQ: ACOR). Civitas' lead program, CVT-301, was in P3 clinical trials to treat devastating OFF-episodes associated with Parkinson's disease. Civitas had raised over \$100 million in equity capital from leading venture capital and crossover investors including Wellington, RA Capital, Adage, Orbimed, Sofinnova and Partner Funds amongst others.

Prior to joining Civitas, Bryan served as Chief of Corporate Development at EKR Therapeutics, a biopharmaceutical business focused on the acute care market, which was sold to Cornerstone Therapeutics (NASDAQ: CRTX) in 2012.

Before EKR, he was one of the first members of the management team at Ovation Pharmaceuticals, where he



was Vice President of Corporate and Business Development and M&A. Ovation was a biopharmaceutical company focused on the acquisition, development, and commercialization of therapies targeted toward specialty markets and rare diseases. Ovation was built through more than a dozen acquisitions and strategic partnerships and was sold to H. Lundbeck A/S in 2009.

Bryan began his career as a healthcare investment banker for William Blair & Company. He holds a Bachelor of Science in Finance with high honors from the University of Illinois at Urbana-Champaign and a Master of Business Administration from the Kellogg School of Management at Northwestern University.

Chris Bryant
Vice President, Technical Operations

Chris brings over 25 years of industry experience in the development biopharmaceutical products, working with industry leading and emerging life sciences companies. Chris joins Kastle from Baxalta where he coordinated all Life-Cycle Management activities associated with their flagship immunology product. Prior to Baxalta, Chris provided consulting services and was the acting Chief Scientific Officer for several newly formed companies, including Sagitta Biotherapeutics and VivacelleBio, Inc.

Chris was previously the Executive Vice President and Chief Scientific Office for Fresenius Kabi, USA, where he had responsibility for the development of a broad portfolio of small molecule injectable generics. In this role, Chris led efforts resulting in the approval of numerous ANDA's as well as several complex 505(b)2 products. Earlier in his career he worked at both Eli Lilly and Armour Pharmaceutical Company, where he began as a bench scientist and went on to gain deep understanding of all facets of drug product development including CMC and clinical development, project management, quality assurance, regulatory affairs and technical operations as he held increasing levels of R&D management responsibility.

Chris holds an undergraduate degree in chemistry from the University of Northern Iowa and earned a Master of Science and Doctorate degree in chemistry from the University of California, San Diego.

Sean McAuliffe
Vice President, Commercial

Sean is a life science industry professional with more than 15 years of U.S. and global sales, sales management, marketing, alliance management and operations experience in start-up, mid-sized, and large pharmaceutical and biopharma companies.

Sean has successfully launched and managed several brands across a broad range of general medicine,



specialty and orphan disease areas. Most recently, Sean was the Global Brand Leader for the launch of Baxalta's latest plasma derived product for patients with primary immune deficiency. In addition to his responsibilities as the Global Brand Leader, Sean was the Commercial Alliance Manager for the alliance between Baxalta and Halozyme, Inc.

Prior to Baxalta, Sean held multiple leadership roles within sales, marketing and alliance management at Takeda Pharmaceuticals North America, G.D. Searle, and Merck & Company.

Sean earned his Bachelor of Arts in Communications from University of Minnesota-Duluth and has completed the Chicago Management Institute Executive Education program through Chicago Booth School of Business.

Michael Shih

Vice President, Business Development and Chief Legal Counsel

Michael has held numerous business development executive roles in biotechnology. Most recently, he was Vice President of Business Development at Epizyme, Inc., a clinical-stage biotechnology company that creates novel epigenetic therapies for cancer patients. At Epizyme, Michael led the transactions to reacquire global rights to Epizyme's EZH2 program, including tazemetostat, from Eisai, and to revise and extend Epizyme's collaboration agreement with Celgene.

Previously, Michael served as senior director of business development at Forest Laboratories, where he was responsible for screening, sourcing and negotiating strategic partnership opportunities. Michael has also held positions at Eisai, where his accomplishments included the licensing of U.S. commercial rights to BELVIQ from Arena Pharmaceuticals, the licensing of U.S. commercial rights to AKYNZEO from Helsinn, and the EZH2 collaboration with Epizyme.

An attorney by training, Michael previously practiced law at several New York firms and held senior legal positions in-house at Eisai Inc., specializing in licensing, corporate transactions, and litigation.

Michael holds a Bachelor of Science in Molecular and Cellular Biology from Cornell University, a Master of Science in Biology from the University of Illinois, and a Juris Doctorate from Fordham University School of Law.